Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial.
- DOI
- 10.1097/ccm.0000000000006608
- Published
- 2025 Apr 1
- Container
- Critical care medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1097/ccm.0000000000006608,
title = {Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial.},
author = {Dargent A and Bourredjem A and Jacquier M and Bohe J and Argaud L and Levy B and Fournel I and Cransac A and Badie J and Quintin L and Quenot JP},
year = {2025},
journal = {Critical care medicine},
doi = {10.1097/ccm.0000000000006608},
url = {https://doi.org/10.1097/ccm.0000000000006608}
}RIS
TY - JOUR TI - Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial. AU - Dargent A AU - Bourredjem A AU - Jacquier M AU - Bohe J AU - Argaud L AU - Levy B AU - Fournel I AU - Cransac A AU - Badie J AU - Quintin L AU - Quenot JP PY - 2025 JO - Critical care medicine DO - 10.1097/ccm.0000000000006608 UR - https://doi.org/10.1097/ccm.0000000000006608 ER -
APA
A, D., A, B., M, J., J, B., L, A., B, L., I, F., A, C., J, B., L, Q., & JP, Q. (2025). Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial.. Critical care medicine. https://doi.org/10.1097/ccm.0000000000006608
Source records
- pubmed · retrieved 2026-11-10T17:59:16.390Z